crane(CR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CR crane

Not Yet Opened 06-04 16:00:00 EDT

188.36

+2.27

+1.22%

盘后188.36

+0.000.00%

16:18 EDT

High189.95	Low186.38	Vol348.62K
Open186.98	D1 Closing186.09	Amplitude1.92%
Mkt Cap10.85B	Tradable Cap9.19B	Total Shares57.60M
T/O65.60M	T/O Rate0.71%	Tradable Shares48.76M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CR","market":"US","secType":"STK","nameCN":"crane","latestPrice":188.36,"timestamp":1780603200000,"preClose":186.09,"halted":0,"volume":348623,"hourTrading":{"tag":"盘后","latestPrice":188.36,"preClose":188.36,"latestTime":"16:18 EDT","volume":42198,"amount":7948415.28,"timestamp":1780604339919,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.01219839862432162,"floatShares":48764858,"shares":57596887,"eps":5.56358,"marketStatus":"Not Yet Opened","change":2.27,"latestTime":"06-04 16:00:00 EDT","open":186.98,"high":189.945,"low":186.38,"amount":65603938,"amplitude":0.019157,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":5.56358,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1780646400000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":186.09,"dividendRate":0.005213,"preHourTrading":{"tag":"盘前","latestPrice":186.09,"preClose":186.09,"latestTime":"07:38 EDT","volume":1,"amount":186.09,"timestamp":1780573092596,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":188.36,"preClose":188.36,"latestTime":"16:18 EDT","volume":42198,"amount":7948415.28,"timestamp":1780604339919,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.680672,"impliedVol":0.3328,"impliedVolPercentile":0.576},"requestUrl":"/m/hq/s/CR/tweets","defaultTab":"tweets","newsList":[{"id":"2640978848","title":"ASCO 2026 | Updated Data from an Oral Presentation of InnoCare's Novel BCL2 Inhibitor Mesutoclax in MDS and AML Released","url":"https://stock-news.laohu8.com/highlight/detail?id=2640978848","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640978848?lang=en_us&edition=fundamental","pubTime":"2026-06-03 10:47","pubTimestamp":1780454820,"startTime":"0","endTime":"0","summary":"BEIJING, June  02, 2026  (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced toda","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/03/3305756/0/en/ASCO-2026-Updated-Data-from-an-Oral-Presentation-of-InnoCare-s-Novel-BCL2-Inhibitor-Mesutoclax-in-MDS-and-AML-Released.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4533","IE00BFXG0V08.USD","ORR","BK4567","LU2413666426.HKD","BK4588","BK4548","LU1721428933.USD","MTD","LU0347712357.USD","LU2413666699.HKD","BK4161","IE00B5TLWC47.USD","BK4121","LU1093756168.USD","IE00BYQQ9H92.USD","LU2211817866.USD","LU1093756325.SGD","BK4585","CR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640111966","title":"Crane Is Maintained at Buy by DA Davidson","url":"https://stock-news.laohu8.com/highlight/detail?id=2640111966","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640111966?lang=en_us&edition=fundamental","pubTime":"2026-06-02 01:46","pubTimestamp":1780335960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 01, 2026 13:46 ET (17:46 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CR","BK4161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640989428","title":"Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640989428","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640989428?lang=en_us&edition=fundamental","pubTime":"2026-06-01 07:30","pubTimestamp":1780270200,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. and SUZHOU, China, May  31, 2026  (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company e","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/31/3303964/0/en/Ascentage-Pharma-Presents-Data-on-Olverembatinib-in-CML-LBP-and-Ph-BCP-ALL-at-ASCO-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","LU1699723380.USD","LU0985320562.USD","BK4139","BK4585","LU1571399168.USD","BK4081","CR","LU2355687059.USD","AAPG","BK4533","BK4588","EMA","BK4107","ALL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640894409","title":"Ascentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640894409","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640894409?lang=en_us&edition=fundamental","pubTime":"2026-06-01 07:30","pubTimestamp":1780270200,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. and SUZHOU, China, May  31, 2026  (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company e","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/31/3303965/0/en/Ascentage-Pharma-Presents-Its-First-Dataset-on-MDM2-p53-Inhibitor-Alrizomadlin-APG-115-in-Pediatric-Solid-Tumors-at-ASCO-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR","CR","LU1223082196.USD","EWS","NB","LU2125909916.SGD","LU2125909759.SGD","LU1223083913.SGD","BK4017","BK4139","BK4161","CDE","APG","LU1923622291.USD","BK4129","BK4168","AAPG","LU1223082519.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639279156","title":"Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits","url":"https://stock-news.laohu8.com/highlight/detail?id=2639279156","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639279156?lang=en_us&edition=fundamental","pubTime":"2026-05-29 20:21","pubTimestamp":1780057260,"startTime":"0","endTime":"0","summary":"Independent Cleveland Clinic Cardiac Review Supports Potential Best-in-Class Safety Profile as MIRACLE Phase 2b/3 Trial Advances HOUSTON, May  29, 2026  (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (N","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/29/3303566/0/en/Moleculin-Presents-ASCO-2026-Data-Demonstrating-No-Detectable-Cardiotoxicity-with-Annamycin-Despite-Exposure-Levels-Far-Exceeding-Conventional-Anthracycline-Limits.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CR","BK4161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638667234","title":"PeproMene Bio Announces Oral Presentation at EHA 2026 Highlighting Favorable Safety and Durable Responses with PMB-CT01 (BAFF-R CAR T-Cell Therapy) in B-cell Lymphomas, Including After Prior CD19 CAR T-Cell Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=2638667234","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638667234?lang=en_us&edition=fundamental","pubTime":"2026-05-28 19:00","pubTimestamp":1779966000,"startTime":"0","endTime":"0","summary":"IRVINE, Calif., May 28, 2026 /PRNewswire/ -- PeproMene Bio, Inc. announced today that updated clinical data from its ongoing Phase 1 study evaluating PMB-CT01, an investigational B-cell activating factor receptor -targeted CAR T-cell therapy, have been selected for an oral presentation at the 2026 Congress of the European Hematology Association .\"When cancer progresses following CD19 CAR T therapy, patients face a significant unmet medical need, with very limited treatment options remaining,\" said Larry W. Kwak, M.D., Ph.D., scientific founder of PeproMene Bio. \"These durable CRs clinically validate BAFF-R as a novel target, while the favorable safety profile observed to date may support future use in outpatient community oncology settings and further exploration in refractory autoimmune diseases.\". PeproMene Bio, Inc. is a clinical-stage biotech company in Irvine, California developing novel therapies to treat cancers and immune disorders. For more information, c","market":"hk","thumbnail":"https://mma.prnewswire.com/media/1972356/Pepromene_Bio_Inc__Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/1972356/Pepromene_Bio_Inc__Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/pepromene-bio-announces-oral-presentation-at-eha-2026-highlighting-favorable-safety-and-durable-responses-with-pmb-ct01-baff-r-car-t-cell-therapy-in-b-cell-lymphomas-including-after-prior-cd19-car-t-cell-failure-302783633.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","IE0031619046.USD","LU2065731478.USD","BK4006","IE00B66KJ199.SGD","LU0963586101.USD","BK7095","BK4187","IE00B7SZL793.SGD","CRS.AU","MRD.AU","CRS","IE00B19Z4B17.USD","BK4230","BK4022","CAR","CR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637116373","title":"2026 ASCO | Pivotal Data of InnoCare's Novel BCL2 Inhibitor Mesutoclax Released","url":"https://stock-news.laohu8.com/highlight/detail?id=2637116373","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637116373?lang=en_us&edition=fundamental","pubTime":"2026-05-22 20:00","pubTimestamp":1779451200,"startTime":"0","endTime":"0","summary":"BEIJING, May  22, 2026  (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/22/3300080/0/en/2026-ASCO-Pivotal-Data-of-InnoCare-s-Novel-BCL2-Inhibitor-Mesutoclax-Released.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","IE00B64QTZ34.USD","ORR","IE00BLDYK493.USD","BK4211","BK4161","TLS","PFS","PB","CR","BK4097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637365900","title":"Ascentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2637365900","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637365900?lang=en_us&edition=fundamental","pubTime":"2026-05-22 08:00","pubTimestamp":1779408000,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. and SUZHOU, China, May  21, 2026  (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company e","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/22/3299861/0/en/Ascentage-Pharma-Releases-Latest-Clinical-Data-from-Multiple-Trials-at-ASCO-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR","EWS","PFS","BK4161","LU1169589451.USD","LU1169590202.USD","PD","BK4139","BK4023","NB","BK4195","AAPG","BK4168","CR","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637357568","title":"Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin","url":"https://stock-news.laohu8.com/highlight/detail?id=2637357568","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637357568?lang=en_us&edition=fundamental","pubTime":"2026-05-22 05:02","pubTimestamp":1779397320,"startTime":"0","endTime":"0","summary":"HOUSTON, May  21, 2026  (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that an abstract featuring pooled cardiac safety data for its lead d","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/21/3299792/0/en/Moleculin-Highlights-Abstract-Accepted-for-Poster-Presentation-at-the-2026-ASCO-Annual-Meeting-Highlighting-Cardiac-Safety-Data-for-Annamycin.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CR","BK4161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637357564","title":"Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC","url":"https://stock-news.laohu8.com/highlight/detail?id=2637357564","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637357564?lang=en_us&edition=fundamental","pubTime":"2026-05-22 05:00","pubTimestamp":1779397200,"startTime":"0","endTime":"0","summary":"At a median follow-up of three years,1500mg of ficerafusp alfa weekly in combination with pembrolizumab demonstrated an estimated 31% overall survival, approximately doubling OS compared to a retrospe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/21/3299780/0/en/Ficerafusp-Alfa-Plus-Pembrolizumab-Demonstrated-Differentiated-Three-Year-Overall-Survival-and-Deep-Responses-Driven-by-TGF-%CE%B2-Inhibition-in-1L-R-M-HPV-Negative-HNSCC.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4124","BK4571","LU0269904917.USD","BK4563","IE00BYQNZ168.SGD","PFS","LU0359202008.SGD","BK4211","LU0456842615.SGD","BK4195","LU1023057109.AUD","01698","LU0359201612.USD","LU2039709279.SGD","IE00BYTNYN87.SGD","BK4531","BK4565","BK4108","CR","BK4548","BK4161","LU0828238088.HKD","TME","BK4509","BK4526","BK4535","BK4552","IE00B12V2V27.USD","SG9999011746.SGD","LU0509642566.USD","CPS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637843043","title":"Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2","url":"https://stock-news.laohu8.com/highlight/detail?id=2637843043","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637843043?lang=en_us&edition=fundamental","pubTime":"2026-05-21 18:00","pubTimestamp":1779357600,"startTime":"0","endTime":"0","summary":"– Of first 20 patients, all four MRD-negative patients have converted to complete response (CR) – – CR rate now 95% (19 of 20 patients) – – All CRs reached within 1 year of follow-up post-dosing – – N","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/21/3299108/0/en/Immix-Biopharma-Announces-95-Complete-Response-Rate-in-Interim-Update-From-relapsed-refractory-AL-Amyloidosis-Clinical-Trial-NEXICART-2.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODD","BK4161","IE0009354923.USD","IE0034390439.USD","BK4022","LU1169590202.USD","AL","BK4572","LU1169589451.USD","BK4230","BK4104","IE00B19Z6F94.USD","CAR","CR","BK4183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635772538","title":"Press Release: Tempest Reports First Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635772538","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635772538?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:15","pubTimestamp":1778789700,"startTime":"0","endTime":"0","summary":"Announced Cincinnati Children's Applied Gene and Cell Therapy Center  as Lead Manufacturing Partner. Appointed Andrew Fang, Ph.D., as Head of Business Development. BRISBANE, Calif., May 14, 2026  -- Tempest Therapeutics, Inc.  , a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy product candidates to treat cancer, today reported financial results for the quarter ended March 31, 2026, and provided a corporate update.\"We made strong progress in the first quarter as we continued to execute across our lead program TPST-2003,\" said Matt Angel, Ph.D., President and Chief Executive Officer of Tempest. \"We advanced key activities supporting the planned initiation of our U.S. registrational study of TPST-2003 in patients with rrMM, including announcing our lead manufacturing partner AGCTC and taking delivery of the TPST-2003 lentiviral vector, a critical component in the manufacturing of TPST-2003. At the same time, we strengthened our ability to unlock ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","EMD","BK4022","CRS","LU2065731478.USD","IE00B19Z4B17.USD","BK4230","IE00B7SZL793.SGD","BK4187","IE00B66KJ199.SGD","BK4195","BK4139","PFS","CR","IE0031619046.USD","CAR","BK4161","LU0963586101.USD","BK4006","TPST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635746529","title":"Press Release: ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31st, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2635746529","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635746529?lang=en_us&edition=fundamental","pubTime":"2026-05-14 22:47","pubTimestamp":1778770020,"startTime":"0","endTime":"0","summary":"-- Updated positive data from iadademstat in 1L AML unfit patients to be. presented at EHA, with 100% ORR, 93% CRc and 79% strict CR at abstract. -- Ongoing broad expansion of iadademstat clinical development across. PORTICO-2 Phase III trial with vafidemstat in aggression in BPD. -- Strong cash position at the quarter ended March 2026: $25.4 million. \"The iadademstat development platform continues to expand, reinforcing its potential as a high-value hematology and oncology asset,\" Dr. Buesa continued. \"Enrollment is advancing across multiple investigator-sponsored studies at leading U.S. cancer centers and National Cancer Institute-sponsored trials in hematologic malignancies and solid tumors. At the same time, em","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4590","CR","BK4588","BK4581","BK4585","BK4202","BK4161","ET","NCI","SCD","ORR","BK4144","EMA","BK4561","BK4081","PTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635753882","title":"MacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation","url":"https://stock-news.laohu8.com/highlight/detail?id=2635753882","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635753882?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:01","pubTimestamp":1778702460,"startTime":"0","endTime":"0","summary":"Manufacturing operations divestiture sharpens focus on core capabilities in novel drug discovery and developmentManufacturing divestiture and expanded monetization of ZYNYZ royalty anticipated to prov","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/13/3294401/0/en/MacroGenics-Reports-First-Quarter-2026-Financial-Results-and-Highlights-Business-Transformation.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND","BK4007","MGNX","BK4139","CR","PROC","BK4161","PR","BK4213"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635782714","title":"Moleculin Announces Imminent MIRACLE Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical Benchmarks","url":"https://stock-news.laohu8.com/highlight/detail?id=2635782714","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635782714?lang=en_us&edition=fundamental","pubTime":"2026-05-13 20:00","pubTimestamp":1778673600,"startTime":"0","endTime":"0","summary":"Preliminary blinded CR rate for the first 45 subjects in the trial approximates 30% and represents ~67% improvement vs. standard of careFirst 45-subject data unblinding expected before June 30, 2026Pr","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/13/3293939/0/en/Moleculin-Announces-Imminent-MIRACLE-Trial-Unblinding-as-Blinded-Data-Continue-to-Significantly-Outperform-Historical-Benchmarks.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","CR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635278202","title":"ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2635278202","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635278202?lang=en_us&edition=fundamental","pubTime":"2026-05-13 20:00","pubTimestamp":1778673600,"startTime":"0","endTime":"0","summary":"64.5% Probability of Remaining Event-Free at Three Years by Kaplan-Meier Analysis After Achieving Complete Response at Three MonthsFirst and Only FDA-Approved Medicine for Recurrent Low-Grade Intermed","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/13/3293931/0/en/ZUSDURI-Median-Duration-of-Response-Still-Not-Reached-with-64-5-36-month-Duration-of-Response-in-the-Pivotal-ENVISION-Trial.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","CR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635247691","title":"Press Release: Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635247691","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635247691?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:05","pubTimestamp":1778616300,"startTime":"0","endTime":"0","summary":"-- Positive 12-Month Phase 2 data for NDV-01 demonstrated a 95% complete. response  rate at any time and a durable 76% CR rate at 12 months in. high-risk non-muscle invasive bladder cancer , and a 94% CR rate. at any time and a durable 80% CR rate at 12 months in the. -- On track to initiate Phase 3 RESCUE registrational program in second line. covering NDV-01 pharmaceutical formulations and methods of treatment; if. issued, patents claiming priority to the provisional filing would have a. \"The AUA2026 Annual Meeting provides an important opportunity to introduce NDV-01 to the broader urologic community,\" said Raj S. Pruthi, MD, Chief Medical Officer -- Urology of Relmada Therapeutics. \"Our presentations will highlight the 12-month Phase 2 data generated to date for NDV-01, including observed complete responses and safety findings. We wil","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","BK4161","LENZ","CR","BK4007","RLMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634230959","title":"Cellectis Reports Financial Results for the First Quarter 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2634230959","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634230959?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:30","pubTimestamp":1778531400,"startTime":"0","endTime":"0","summary":"Pivotal Phase 2 with lasme-cel in r/r B-ALL (BALLI-01 trial) Pivotal Phase 2 first interim analysis expected in Q4 2026BLA submission anticipated in 2028 Phase 1 with eti-cel in r/r NHL (NATHALI-01 tr","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/11/3292381/0/en/Cellectis-Reports-Financial-Results-for-the-First-Quarter-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0031619046.USD","IE00B19Z4B17.USD","CR","BK4006","CLLS","ORR","LU0963586101.USD","LU2065731478.USD","IE00B66KJ199.SGD","BK4161","BK4139","BK4187","CRS","IE00B7SZL793.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633813369","title":"UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2633813369","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633813369?lang=en_us&edition=fundamental","pubTime":"2026-05-06 20:00","pubTimestamp":1778068800,"startTime":"0","endTime":"0","summary":"ZUSDURI generated revenue of $29.2 million in Q1 2026, representing 109% quarter-over-quarter growth, reflecting broader utilization with the permanent J Code effective January 1, 2026JELMYTO achieved","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/06/3288758/0/en/UroGen-Reports-ZUSDURI-Revenue-More-Than-Doubled-Quarter-over-Quarter-and-Provides-First-Quarter-2026-Financial-Results-and-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VHT","BK4585","BK4161","CR","IND","BK4550","BK4588","IXJ","KOL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632406586","title":"Crane director Susan D. Lynch acquires $26,607 of common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2632406586","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632406586?lang=en_us&edition=fundamental","pubTime":"2026-05-02 04:47","pubTimestamp":1777668450,"startTime":"0","endTime":"0","summary":"Crane Co director Susan D. Lynch reported purchase of 150 common shares at USD 177.38.Directly held stake rose to 370 shares following transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crane Company published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 01, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nNDL9cX7D0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Crane director Susan D. Lynch acquires $26,607 of common shares","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CR","BK4161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.craneco.com","stockEarnings":[{"period":"1week","weight":0.038},{"period":"1month","weight":0.0709},{"period":"3month","weight":-0.0144},{"period":"6month","weight":0.003},{"period":"1year","weight":0.0756},{"period":"ytd","weight":0.0213}],"compareEarnings":[{"period":"1week","weight":0.0033},{"period":"1month","weight":0.046},{"period":"3month","weight":0.126},{"period":"6month","weight":0.1041},{"period":"1year","weight":0.2704},{"period":"ytd","weight":0.1102}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Crane NXT, Co. focuses on payment and merchandising technologies. It indents to offer electronic equipment and associated software leveraging extensive, and proprietary core capabilities, including payment verification and authentication, as well as automation solutions, field service solutions, remote diagnostics, and productivity enhancing software solutions. The company is based in Stamford, Connecticut.","yearOnYearQuotes":[{"month":1,"riseRate":0.543478,"avgChangeRate":0.020828},{"month":2,"riseRate":0.717391,"avgChangeRate":0.036902},{"month":3,"riseRate":0.565217,"avgChangeRate":0.013749},{"month":4,"riseRate":0.617021,"avgChangeRate":0.003315},{"month":5,"riseRate":0.638298,"avgChangeRate":0.009155},{"month":6,"riseRate":0.595745,"avgChangeRate":0.005645},{"month":7,"riseRate":0.586957,"avgChangeRate":0.004401},{"month":8,"riseRate":0.347826,"avgChangeRate":-0.009516},{"month":9,"riseRate":0.369565,"avgChangeRate":-0.022666},{"month":10,"riseRate":0.586957,"avgChangeRate":0.009396},{"month":11,"riseRate":0.543478,"avgChangeRate":0.025826},{"month":12,"riseRate":0.608696,"avgChangeRate":0.018097}],"exchange":"NYSE","name":"crane","nameEN":"crane"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"crane(CR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest crane(CR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"crane,CR,crane股票,crane股票老虎,crane股票老虎国际,crane行情,crane股票行情,crane股价,crane股市,crane股票价格,crane股票交易,crane股票购买,crane股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"crane(CR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest crane(CR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction